Stock Spotlight: Fisher & Paykel Healthcare (ASX:FPH)
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Key Stats
Key Stats
Source: Yahoo Finance. Data as of 19/08/25.
Price Performance
Growth Potential
- Solid revenue and earnings growth from 2028 onwards as 2026-2027 are prioritized to best position the company to capture growing demand by building more capacity, refining the go-to-market strategy and enhancing operational efficiency.
- Value accretive M&A with the company expanding the xScale to drive deeper strategic relationships with major hyperscale customers that move into the properties.
- Real estate ownership (own 152 of 260 data centers) and long-term leases (82% of recurring revenue is generated by either owned properties or properties where lease expirations extend to 2039 and beyond).
- Strongest balance sheet among sector and broader REIT players (net leverage of 3.4x is ~1.8x below average leverage level of peers) with global exposure allowing it to issue debt in different countries with potentially better debt cost versus the U.S.
- Diversified client base and revenue stream (with ~90% recurring revenue).
Key Risks
- Over leveraged balance sheet in an economic downturn or recession.
- Higher operating expenses – particularly electricity costs. However, the contracts between Equinix and its customers provide for rights and protection clauses to permit the Company to pass on electricity cost increases that exceed 5%.
- Rising technology and acceptance of cloud-based services may incentivise businesses to fully leverage cloud infrastructure rather than connecting with IBX data centres. However, management has downplayed these concerns, noting there must still be direct interconnection between Cloud & businesses within the data centres.
- Increased competition in the industry from the likes of Google, Apple, Microsoft and Digital Realty Trust (incl. formation of strategic alliances amongst competitors).
- The REIT classification mandates a minimum of 90% of taxable income paid to shareholders. This may hinder EQIX’s ability to increase its cash via retained earnings and could render the Company’s balance sheet inflexible.
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.









